sglt2 inhibitors and haemoglobin increase: a possible explanation of the cardiovascular benefits?
Published 12 days ago • 339 plays • Length 59:16Download video MP4
Download video MP3
Similar videos
-
1:00:55
sglt2i for evidence based cardiorenal protection in diabetic and non-diabetic chronic kidney disease
-
23:14
#12 sglt2i / mras / glp1s, with katherine tuttle
-
2:59
assimilating the evidence in t2dm: cardiovascular and renal outcomes with sglt2 inhibitors
-
3:40
using sglt2 inhibitors to achieve cardiovascular benefits
-
6:11
benefits of sglt2 inhibitors and glp-1 receptor agonists
-
1:23:07
sglt2 inhibitors & cardiovascular outcome
-
22:15
sglt-2 inhibitors for type 2 diabetes - amel arnaout, md
-
3:35
sglt-2 inhibitors, explained: how they work, their benefits and risks
-
8:15
sglt2 inhibitors and heart failure
-
18:05
emerging t2dm therapies targeting the kidney
-
16:24
how sglt2 inhibitors protect the kidney
-
1:06:15
a tale of salt and sugar: sglt2 inhibitors in cardiovascular disease
-
55:47
treatment of diabetes- update and physiologic approach 3/29/17
-
26:43
prof melanie davies - 'do glp-1 analogues and sglt2 inhibitors have a role beyond type 2 diabetes?'
-
1:05:57
diabetic kidney disease (new pharmacological approach) e-seminar #2
-
1:00:20
sglt2 inhibitor interdisciplinary forum
-
58:42
type 2 diabetes: new guidelines and controversies
-
10:37
cardiovascular outcomes in new users of sglt-2 inhibitors